Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Uveitic Macular Edema Increases Costs Among Patients With Noninfectious Uveitis
November 12th 2021Uveitic macular edema is common in patients with noninfectious uveitis, and its significant burden on patients and payers warrants more specific treatment guidelines to minimize quality-of-life and economic effects.
Read More
Analysis of Nusinersen Shows Favorable Safety Profile in Adults With SMA
November 11th 2021Data on nusinersen’s safety profile in adult patients are more limited than in infant and adolescent patients, but a recent study showed positive results based on cerebrospinal fluid and blood sample parameters.
Read More
Nonadherence to Nusinersen Treatment Increases Health Care Utilization, Costs in SMA
November 5th 2021Results of a retrospective claims database analysis suggest that adherence to scheduled intrathecal nusinersen injections may lead to improvements in comorbidities, health care utilization, and costs for spinal muscular atrophy (SMA) types 1, 2, and 3.
Read More
Case Study Suggests Further Research on Benign Focal Hepatic Lesions in ASMD
November 5th 2021Imaging studies and subsequent biopsies of a liver lesion showed a foamy macrophages aggregate in a 30-year-old patient with acid sphingomyelinase deficiency (ASMD) similar to those found in Gaucher disease.
Read More
Study Evaluates Potential Cerebrospinal Fluid Biomarkers in SMA Treatment
October 30th 2021The single-center study explored cerebrospinal fluid neurofilament and protein levels in patients with spinal muscular atrophy (SMA) undergoing treatment with nusinersen in an effort to identify useful biomarkers as treatment options expand.
Read More
Researchers Hope Single-Cell Tumor Immune Atlas Can Improve Predictions in Precision Oncology
October 26th 2021A pan-cancer reference atlas provides a framework for an immune-based patient stratification that study authors expect to be predictive for patient prognosis and immunotherapy response at an elevated level after further studies.
Read More
More SMA Biomarkers Are Needed to Gauge Disease Progression, Therapy Response
October 21st 2021A review of current molecular and electrophysiological biomarkers in spinal muscular atrophy (SMA) concluded that more exploration is necessary to find noninvasive, yet accurate, measures of disease progression and therapy response.
Read More
Personalized Dendritic Cell Vaccination Safe, but More Research Needed on Efficacy
October 21st 2021Autologous tumor lysate particle-loaded dendritic cell (TLPLDC) vaccination is well-tolerated in combination with other immunotherapies, but further research is needed to confirm its efficacy.
Read More
Subcutaneous Intrathecal Catheter Allows for Effective Administration of Nusinersen in SMA
October 14th 2021A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection.
Read More
Management of Low-risk ET and PV Has Room for Improvement
October 3rd 2021Despite excellent prognoses in low-risk patients with essential thrombocytopenia (ET) and polycythemia vera (PV), knowledge gaps remain and novel, more tolerable therapies require reevaluation of treatment algorithms.
Read More
Modern Gene Therapies Show Promise in Motor Neuron Disorders
October 3rd 2021A review of current research and drug development in motor neuron disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy shows progress in the identification of treatment pathways and therapies.
Read More